NCT05339074View on ClinicalTrials.gov

Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

February 1, 2026

Study Completion Date

February 28, 2026

Conditions
Bipolar DisorderBipolar DepressionBipolar I DisorderBipolar II Disorder
Interventions
DRUG

Ketamine Hydrochloride

60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg

Trial Locations (3)

M5G 2C4

RECRUITING

Toronto General Hospital, Toronto

M5T 2S8

RECRUITING

Toronto Western Hospital, Toronto

L1N 5S9

ACTIVE_NOT_RECRUITING

Ontario Shores Centre for Mental Health Sciences, Whitby

All Listed Sponsors
lead

Joshua Rosenblat

OTHER